



Risk factors predictive of adverse drug events and drug-related falls in aged care residents: secondary analysis from the ReMInDAR trial

Gereltuya Dorj¹ · Nibu Parameswaran Nair² · Luke Bereznicki² · Lan Thu-Kelly¹ · Nicole Pratt¹ · Lisa Kalisch Ellet³ · Andre Andrade¹ · Debra Rowett³ · Joseph Whitehouse⁴ · Imaina Widagdo¹ · Rebecca L. Bilton¹ · Renly Lim¹ · Elizabeth Roughead¹

Accepted: 12 October 2022
© The Author(s) 2022

Abstract

Background Residents of aged-care facilities have high rates of adverse drug events. This study aimed to identify risk factors for adverse drug events in aged-care residents.

Method This was a secondary study using data from a multicentre randomised controlled trial. Data from 224 residents for whom there was 6 months of baseline information were analysed. We assessed the risk of adverse drug events and falls (post hoc) in the subsequent 6 months. Adverse events were identified via a key word search of the resident care record and adjudicated by a multidisciplinary panel using a modified version of the Naranjo criteria. Covariates identified through univariable logistic regression, including age, sex, medicines, physical activity, cognition (Montreal Cognitive Assessment), previous adverse events and health service use were included in multivariable models.

Results Overall, 224 residents were included, with a mean age of 86 years; 70% were female. 107 (48%) residents had an adverse drug event during the 6-month follow-up. Falls and bleeding were experienced by 73 (33%) and 28 (13%) residents, respectively. Age (odds ratio [OR] 1.05, 95% confidence interval [CI] 1.01–1.10), weight (OR 1.02, 95% CI 1.002–1.04), previous fall (OR 2.58, 95% CI 1.34–4.98) and sedative or hypnotic medicine use (OR 1.98, 95% CI 1.52–2.60) were associated with increased risk of adverse drug events. Increased cognition (OR 0.89, 95% CI 0.83–0.95) was protective. Risk factors for falls were previous fall (OR 3.27, 95% CI 1.68–6.35) and sedative or hypnotic medicines (OR 3.05, 95% CI 1.14–8.16). Increased cognition (OR 0.88, 95% CI 0.83–0.95) was protective.

Conclusion Our results suggest residents with a previous fall, reduced cognition, and prescription of sedative or hypnotic medicines were at higher risk of adverse drug events and should be considered for proactive prevention.

Key Points

Residents of aged-care facilities have high rates of adverse drug events, identifying the risk factors predicting adverse drug events are important to reduce medicine-induced harm in older residents living in aged-care facilities.

Older people living in residential aged-care facilities demonstrating clearly identifiable characteristics, including poor cognition performance, previous fall, increased age or weight, or prescribed sedative or hypnotic agents, should be prioritised for medicines review to consider medicines that can be ceased and to identify changes in symptoms that may indicate deterioration or adverse drug events.

✉ Gereltuya Dorj
gereltuya@gmail.com; dorjg@who.int

¹ Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, SA, Adelaide, Australia

² School of Pharmacy and Pharmacology, University of Tasmania, TAS, Hobart, Australia

³ School of Pharmacy, Clinical and Health Sciences, University of South Australia, SA, Adelaide, Australia

⁴ Pharmacy Improvement Centre Ltd, SA, Welland, Australia

1 Introduction

Approximately 8% of Australians aged 65 years and over are residents of aged-care facilities [1]. These residents are vulnerable to medication-related harms due to their older age, multimorbidity, frailty, frequent care transitions, polypharmacy, and suboptimal medication use [2–4]. The rate of adverse drug events in aged care ranges from 1 [5] to 27 [6] per 100 resident months. The global estimates of medicine-related harm exceeds over \$40 billion every year [7], while more than 40% of medicine-related adverse events are considered preventable [8].

There are several published definitions for medications classified as potentially inappropriate (PIMs) and potentially causing medicine-related harm for elderly adults, including the Beers criteria [9], the Screening Tool of Older Persons' Prescriptions (STOPP), the Screening Tool to Alert to Right Treatment (START) [10], the Drug Utilization Review [11], the Medication Appropriateness Index [12], and the National Committee of Quality Assurance [13]. Among these criteria, the Beers criteria and STOPP criteria are the most commonly referenced. PIMs are recommended to be avoided when treating older people, however due to different continents and different criteria, caution must be exercised when interpreting the observed association between the number of PIMs and negative health outcomes in older adults [14].

Among the PIMs, known high-risk medications (e.g., sedatives and antipsychotic medicines) contribute significantly to adverse drug events in aged-care residents, and are important precipitating factors for falls and acute disease states, as well as contributing to the overall medicine-related burden [15, 16]. In a feasibility trial in aged-care facilities, deprescribing anticholinergic and sedative medicines was associated with significant benefits across a range of important health measures, including mood, frailty, falls and reduced adverse drug events [17].

A novel model of care is necessary within aged-care settings to prevent medication-related harm and improve the quality use of medicines [18]. One potential strategy for preventing adverse drug events is to identify residents who are at higher risk of adverse drug events through formal risk assessment processes so that additional medicine management services can be directed towards this group [19].

We located two prior studies of risk factors, both in the US aged-care setting [8, 20]. The findings from these studies suggest that being a new resident, taking specific medicines, including antibiotics, antipsychotics, or antidepressants, and having comorbidities were all associated with increased risk of adverse drug events [8, 20]. The generalisability of the risk models to other sites is unknown [8, 20].

Risk prediction models for medication-related harms in elderly patients in acute care and community settings are

more commonly reported and include the Prediction of Hospitalization due to Adverse Drug Reactions in Elderly Community-Dwelling Patients) score (PADR-EC score) [21], Medicine Risk Score (MERIS) [22], Geriatric Adverse Drug Reaction Score (GerontoNet Score) [23], and Prospective study to develop a model to stratify the RISK of Medication-related harm in hospitalized Elderly patients (PRIME) [24]. However, none of these risk models were developed or tested in residential aged-care populations.

In 2019, the Australian government announced \$25.5 million in funding for aged-care medication management programmes, including more frequent medication reviews to reduce the use of medication to influence resident's behaviour in aged-care settings [25]. Further research is needed to inform the implementation of this policy, including the identification of residents who should be prioritised for follow-up. Identifying independent risk factors for adverse drug events, and validated adverse drug event-focused risk stratification models will enable the aged care staff, general practitioners and pharmacists to consider their residents' risk of medication-related harm as part of routine practice [20]. We aimed to identify independent risk factors for adverse drug events and falls as these events are frequently reported in the aged-care settings.


2 Methods

This study was a secondary post hoc analysis of data from a multicentre randomised controlled trial (ReMInDAR trial) to determine the effectiveness of a 12-month pharmacist service compared with usual care in reducing medicine-induced deterioration, frailty and adverse drug events in older people living in residential aged-care facilities in Australia [26]. Medicine-induced deterioration can be caused by pharmacodynamic effects of medicine or result from the effects of medicines contributing to frailty, cognition, activity or loss of appetite [27–30]. Identification and management of medicine-induced deterioration may support preventing frailty and adverse drug events in older adults [31, 32].

Pharmacists visited residents enrolled in the intervention group every 8 weeks over 12 months, assessing signs and symptoms of medicine-induced deterioration. The pharmacist service included review or care record and medication chart, discussion with resident and care staff, and resident assessment using validated tools. Recommendations concerning medication management were made to the residents' general practitioners.

At enrolment, a total of 248 residents were recruited from 39 residential aged-care facilities across two Australian states (South Australia and Tasmania); data were collected between August 2018 and July 2020. Residents were excluded if they had significant existing frailty, had

Fig. 1 Variables included in the analysis, by corresponding data collection points



moderate or severe dementia, or were involved in another research project [26]. The median number of beds of participating residential aged-care facilities was 92 (range 29–184). Residents were included if they were using four or more medicines at the time of recruitment or were taking at least one medicine with anticholinergic or sedative properties [26]. At 6 months, 24 residents were deceased, hence in this study, we included a total of 224 residents whose data were available (Fig. 1).

The final months of the ReMInDAR trial (March–July 2020) were affected by global pandemic restrictions due to coronavirus disease 2019 (COVID-19). Although no facilities experienced outbreaks, 53 (9%) pharmacist visits had to be undertaken remotely or were delayed and 35 (6%) were unable to be performed. Twelve-month assessments of 150 (67%) residents were affected.

The study was approved by the Human Research Ethics Committee of the University of South Australia (ID: 0000036440) and the University of Tasmania (ID: H0017022).

2.1 Data Collection

Data collection was based on reviewing residents’ health care records and identifying any new-onset illnesses or adverse events present since the last assessment. All residents were assessed by research assistants at baseline and at 6 and 12 months. We used the 6-month trial measure as the baseline point for this study as it provided a 6-month

history for identification of risk factors. We then used the 6- to 12-month time period to ascertain the occurrence of the outcome, which was post risk factor identification (see Fig. 1).

2.2 Outcomes

The primary outcome of interest in this study was adverse drug events. We assessed each resident to determine whether they experienced an adverse drug event between 6 and 12 months following their enrolment in the study. Since falls was the most frequent adverse drug event, we conducted a post hoc analysis with fall as the outcome to investigate any difference in risk factors for adverse drug events and falls.

2.3 Assessment of Adverse Drug Events

Adverse events were collected by key word search of the resident care records by research assistants. The key words were predefined as falls (non-injurious and injurious, including fractures), bleeding, bruising, confusion, cough, dizziness, delirium events, urticaria, gastroenteritis, vomiting, nausea, delirium events, bowel or urinary changes, hospitalisation and others. These adverse events were reviewed to assess event type and causality. Initially, the adverse events were independently coded by two research pharmacists (GD, LKE) for causality using the Naranjo algorithm (33). Adverse events were classified as definite (score from 9 to 12), probable (score from 5 to 8), possible (score from 1

to 4), or doubtful (score from 0 to -2) [34]. Classification of the adverse event was submitted to a multidisciplinary panel of clinicians (AA, DR, JW) for confirmation. Of 1978 adverse drug events identified in the 12-month period of the ReMInDAR trial, 30% ($n = 583$) were judged as possible, probable, or definite adverse medicine events [26]. In this analysis, we included 325 adverse drug events that were experienced between baseline and 6 months.

2.4 Independent Variables

A range of physical and cognitive functions that are components of frailty can be affected by medicine use. In older adults, medicines, in particular medicines with sedative and anticholinergic properties, significantly worsen frailty [31]. When compared with the non-frail population, frail older people are more vulnerable to adverse drug events [35]. Evidence suggests that the odds of developing adverse drug events in frail people was double that of non-frail individuals (29% compared with 17%, respectively; odds ratio [OR] 2.1, 95% confidence interval [CI] 1.5–3.0) [36]. In this analysis, we included measurements assessing the variables such as cognition, frailty, physical activities, and hand grip strength, as well as medicines use and doctors' visits. In aged-care facility residents, the Frailty Index (FI) has been shown to have good predictive ability for adverse events [37, 38]. Other risk factors in older people include cognitive impairment [38], physical activity and sedentary behaviour, sleep time [39], and grip strength [40].

2.5 Continuous Variables

Descriptive information of residents, analysed as continuous variables, were age, weight, frailty, physical activity, sedentary behaviour, sleep time, cognition, hand grip strength, count of regularly scheduled medicines, counts of hospitalisations, emergency department visits and doctors visits during the 6-month baseline period.

Frailty was evaluated using the FI [37]; an FI score of ≥ 0.4 is suggestive of existing significant frailty. The grip strength was measured using a hand-held dynamometer (best of three from the dominant hand) [41]. The physical activities indicating residents' physical activities, including light, moderate-to-vigorous, and moderate intensity, as well as sedentary behaviour (sitting or lying down) and sleep times were assessed using the GENEActive research grade activity tracker [39].

The GENEActive was worn on the wrist by residents for a 7-day period [26]. In older adults, 6–8 h of daily sleep was considered to be within the normal range [42]. Studies assessing physical measurements with GENEActive were reported to range between 538 and 630 min for sedentary

activity, 103 and 209 min for light activity, and 134 and 141 min for moderate–vigorous activity in older adults [43].

Cognition was assessed using the Montreal Cognitive Assessment (MoCA) test [44], which has a score between 0 and 30, with a higher score indicating better cognition. A score of ≤ 17 indicates dementia [44]. Medicine use was collected from the facility-maintained medication chart by independent research assistants, and health service use was based on hospital, emergency and doctors' claims data.

2.6 Categorical Variables

Covariates included sex, intervention status, and previous adverse drug events and falls recorded in the first 6 months of the trial. Furthermore, use of any medicines within each of the following medicine classes were analysed: Alzheimer disease treatments, antibiotics or anti-infectives, anticholinergics, anti-gout medicines, antihistamines, antihyperlipidemics, antineoplastics, antiparkinsonians, antipsychotics, antiseizure medicines, antithrombotics (anticoagulants and antiplatelets), antihypertensives, diuretics, gastrointestinal medicines, hypoglycemics, muscle relaxants, opioid and non-opioid analgesics, antidepressants, nutrients or supplements, osteoporosis medicines, sedatives and hypnotics, and thyroid medicines.

Inpatient hospitalisations, emergency department visits and doctors' visits in the 6 months prior were calculated using the hospital records as well as Medicare Benefit Schedule (MBS) claims. The MBS contains a list of health professional services subsidised by the Australian Government for a wide range of health services, including consultations, diagnostic tests and operations [45].

A binary variable indicating residents whose 12-month assessments were affected by COVID-19 access restrictions was also considered for inclusion as a covariate.

2.7 Statistical Analysis

Participant characteristics are presented as descriptive statistics: mean (standard deviation [SD]), median (interquartile range [IQR]) or count (percent [%]), as appropriate.

Specific medicines and total count were analysed at the level of unique medicine, classified using the Anatomical Therapeutic and Chemical codes (46). See electronic supplementary material [ESM] Table S1 for medicines with sedative and hypnotic properties that were assessed in the study.

For both binary outcomes, univariable logistic regression modelled each risk factor separately. Variables with a p -value < 0.1 were included in a multivariable model, as well as intervention status. Variables considered for selection included age, weight, frailty, physical activity, cognition, hand grip strength, count of regularly scheduled

medicines, specific medicines, counts of hospitalisations, emergency department visits and doctors' visits, adverse drug events occurring during the 6-month baseline period, and whether 12-month assessments were affected by COVID-19 restrictions. Linearity of continuous variables was assessed graphically.

There were missing data for 12 residents who refused or were unable to complete the MoCA assessment at 6 months and there were two residents where specific medicine information was unavailable. Eleven residents had missing data for weight at 6 months. Multiple imputation with chained equations for missing data was performed using the R package 'mice' [47]. One hundred iterations were used and estimates combined using Rubin's rules [48]. Binary data were imputed using logistic regression and weight with linear regression. Since cognition was limited to 0–30, predictive mean matching was used, which has been found to produce adequate association estimates for bounded variables [49]. In the final multivariable model, covariates and interactions were retained if $p < 0.1$.

Results are presented as ORs and 95% CIs. Analyses were performed using R Version 4.2.1 (R Foundation for Statistical Computing, Vienna Austria) [50].

2.7.1 Model Performance

The predictive discrimination of the optimum models for adverse drug events were assessed using the concordance statistic (C-statistic). The predictive discrimination refers to the ability of a model to clearly distinguish between the two binary outcome categories; a value of C-statistic above 0.7 is considered acceptable [51]. The pooled C-statistic was calculated using the R package 'miceafter'.

We tested the multicollinearity of the variables and the strength of the correlation by estimating the variance inflation factors (VIFs), with a VIF < 5 considered to indicate no collinearity [52].

3 Results

The characteristics of 224 residents measured at the 6-month timepoint are shown in Table 1. The mean age of residents was 86 years (SD 8) and 70 (31%) were male.

In the 6-month baseline period, 165 (74%) residents had claims for doctors visits, 26 (12%) residents had an inpatient hospitalisation, and 29 (13%) participants had an emergency department visit (median 1, IQR 0–2). Ninety (40%) residents had a history of adverse drug events and 60 (27%) had a previous fall. The median number of regularly scheduled medicines was 11 (IQR 8–14), with 184 (83%) residents prescribed sedative or hypnotic medicines. Frequencies of

other prescribed medicines are reported in ESM Table S2. The median MoCA score was 22 (IQR 18–25). Mean sleep time was 8.9 h (SD 1.1), which is higher than the normal range in older adults of 6–8 h.

3.1 Frequency and Type of Adverse Drug Events

Almost half of all residents had at least one adverse drug event between 6 and 12 months ($n = 107$, 48%). Falls were the most frequent event, experienced by 73 (33%) residents, followed by bleeding reported in 28 (13%) residents (Table 2). Bleeding was most likely attributed to the use of antithrombotic medicines (anticoagulants and antiplatelets).

3.2 Risk Factors

Factors independently associated with a higher risk of having an adverse drug event included age (OR 1.05, 95% CI 1.01–1.10), weight (OR 1.02, 95% CI 1.002–1.04), previous fall (OR 2.58, 95% CI 1.34–4.98) and prescribing of sedative or hypnotic medicines (OR 2.25, 95% CI 1.01–5.00) [Table 3]. A higher MoCA score was protective (OR 0.89, 95% CI 0.83–0.95). The model had a moderate predictive power, with C-statistic equal to 0.73 (0.66–0.79). No collinearity was detected (VIF < 5 for all variables). There were no significant interactions.

For falls, the risk was higher when a resident had had a previous fall (OR 3.27, 95% CI 1.68–6.35) or used sedative or hypnotic medicines (OR 3.05, 95% CI 1.14–8.16) [Table 4]. Increased MoCA score was protective (OR 0.88, 95% CI 0.83–0.95). The model for falls showed moderate power (C-statistic = 0.75, 0.67–0.81), no collinearity was identified, and no interactions were significant. All covariates identified in univariable analysis are shown in ESM Tables S3 and S4.

4 Discussion

We found previous falls, lower cognition scores, and sedative and hypnotic medicine use were predictive of both future adverse drug events and falls in residents. In addition, age and weight increased the risk of adverse drug events. The risk factors reported in our study are possible to identify during clinical reviews and thus could be used for prioritising residents at risk of harm from medicines.

The predictors we identified are supported by other research. Sedative and hypnotic medicines are well recognised as a cause of adverse drug events. A case-control nested study assessed the risk factors for adverse events among US residents. Adverse drug events were identified in 410 nursing home residents and independent risk factors

Table 1 Principal characteristics of the study population at 6 months

Characteristic [N = 224] ^a	
Age, years [mean (SD)]	86 (8)
Intervention group [n (%)]	105 (47)
Weight, kg [mean (SD)]	74 (18)
Male sex [n (%)]	70 (31)
Number of regularly scheduled medicines [median (IQR)]	11 (8–14)
Use of sedative or hypnotic medicines (N = 222) [n (%)]	184 (83)
Frailty Index [mean (SD)]	0.29 (0.1)
Highest grip strength (N = 208) [mean (SD)]	17.6 (7.7)
MoCA score (N = 212) [median (IQR)]	22 (18–25)
Sedentary time, hours (N = 122) [mean (SD)]	12.6 (1.5)
Sleep time/in bed, hours (N = 122) [mean (SD)]	8.9 (1.1)
Light activity time, hours (N = 122) [median (IQR)]	1.5 (0.9–2.2)
Moderate and vigorous activity time, hours (N = 122) [median (IQR)]	0.5 (0.2–1.1)
Any visit to emergency department [n (%)]	29 (13)
Number of visits to the emergency department [median (IQR)]	1 (0–2)
Any hospital admission [n (%)]	26 (12)
Number of hospital admissions [median (IQR)]	1 (0–4)
Any outpatient hospital care [n (%)]	165 (74)
Number of outpatient care episodes [median (IQR)]	12 (0–22)
Previous adverse drug event (baseline–6 months) [n (%)]	90 (40)
Previous fall (baseline–6 months) [n (%)]	60 (27)
Affected by COVID-19 lockdowns [n (%)]	150 (67)

SD standard deviation, IQR interquartile range, MoCA Montreal Cognitive Assessment, COVID-19 coronavirus disease 2019

^aUnless indicated otherwise

Table 2 Classification of adverse drug events

Type of adverse medicine events	Number of residents (n = 107)	Number of adverse drug events (n = 325)
Fall	73	191
Bleeding (any)	28	53
Bruising	17	30
Dizziness	15	18
Confusion	4	14
Constipation	4	4
Urticaria (rash)	3	4
Cough	2	2
Gastroenteritis, vomiting, nausea	3	3
Faecal impaction	1	1
Other ^a	4	5

^aIncludes skin tear, spontaneous eye bleeding, red eye with discharge

identified were schedule of sedatives and hypnotics (cases, 33.4% vs. controls, 23.7%; $p < 0.01$) [20].

Table 3 Multivariable logistic regression of risk factors for having any adverse drug event

Variable	OR (95% CI)	p-Value
Group: Intervention	1.28 (0.71–2.32)	0.41
Age ^a	1.05 (1.01–1.10)	0.018
Weight, kg	1.02 (1.002–1.04)	0.028
MoCA ^b	0.89 (0.83–0.95)	<0.001
Previous fall	2.58 (1.34–4.98)	0.005
Sedatives or hypnotics	2.25 (1.01–5.00)	0.047

OR odds ratio, CI confidence interval, MoCA Montreal Cognitive Assessment

^aEvery year increase

^bEvery point increase

A 2008 literature review assessing medicine-induced errors in acute care settings also reported that sedative medicines were the medicines commonly implicated [53].

We found increased cognition to be protective against adverse drug events. Similar findings were reported in systematic reviews (54, 55), with poorer cognitive performance

Table 4 Multivariable logistic regression of risk factors for having a fall

Variable	OR (95% CI)	<i>p</i> -Value
Group: intervention	0.86 (0.46–1.62)	0.64
Weight, kg	1.02 (0.999–1.03)	0.07
MoCA ^a	0.88 (0.83–0.95)	<0.001
Previous fall	3.27 (1.68–6.35)	<0.001
Sedatives or hypnotics	3.05 (1.14–8.16)	0.03

OR odds ratio, CI confidence interval, MoCA Montreal Cognitive Assessment

^aEvery point increase

significantly associated with higher mortality rates, dementia, decreased activity, hospitalisation and reduced quality of life [54, 55]. We did not locate any studies assessing the association between the risk of adverse events and cognition when measured using the MoCA. For this reason, direct comparison of our results with other studies is difficult; however, our findings reinforce the need to prioritise residents with cognitive impairment.

Previous studies have shown frailty is associated with adverse drug events (31, 35). In our study, frailty was measured using the FI and was not observed to be an independent predictor, which may be due to the fact that non-frail residents were enrolled in our study.

Increasing age is a significant contributing factor to ADR for adverse drug events in older residents [56]. In our study, with every additional year, residents are at a 5% higher risk of having an adverse drug event (OR 1.05, 95% CI 1.01–1.10; $p = 0.018$). No comparable findings were reported in other studies. Furthermore, a significantly associated risk factor for adverse drug events was the weight of residents in our study. The mean baseline body weight was 74 kg, suggesting that our findings could be validated in another sample.

Falls are frequent in aged care, with estimates that one in two Australian residents living in aged care fall within a 6-month period [15]; a previous fall is also recognised as one of the strongest predictors of falls [57]. A systematic review analysing the risk factors for falls included 15 studies performed in aged-care residents (mean age 80 years) [58]. Overall, the association with a previous fall was threefold (OR 3.06, 95% CI 2.12–4.41), which was confirmed in our study [58].

We found using medicines with sedative and hypnotic properties was an independent factor for falls. A meta-analysis of the impact of nine medication classes on falls in older residents assessed the association between falls

and sedative hypnotics, and found the risk of falling was lower than our findings (OR 1.47, 95% CI 1.35–1.62) [59]. Further support for our results comes from a previous systematic review assessing the evidence linking drugs with falls in older people. The risk for falls was higher in those prescribed sedatives and hypnotic medicines (OR 1.54, 95% CI 1.40–1.70) [60].

In our study, the count of prescribed medicines was not found to be a predictor for adverse drug events. The association between risk of having an adverse outcome and polypharmacy in the aged-care population is not universally confirmed in the literature [61, 62]. In aged-care settings, almost 50% of the population is exposed to five or more medicines [61]. This may indicate that the type of medicines used have a more important impact on risk for experiencing adverse drug events rather than the count of medicines.

4.1 Strengths and Limitations

To our knowledge, this is the first study to identify risk factors associated with adverse drug events in older residents living in aged-care facilities, where data were collected longitudinally. Longitudinal measurements pertaining to older residents' cognitive and physical function, as well their medicine use, were objectively collected by the ReMInDAR staff, who received training on using validated scales such as the GENEActiv activity tracker [39] and MoCA prior to engaging in the trial [26, 37, 41, 44]. Data on inpatient and outpatient hospitalisations, as well as emergency visits, were comprehensive, as they were obtained employing the claims from health service use.

The analysis did not specifically focus on PIMs because this required an extra decision-making process. In order to detect specific medicines, we included all medicine classes, without limiting to PIMs only.

The model fit was evaluated using the C-statistic; all models indicated a good fit with a C-statistic > 0.7. However, a limitation of our results is that the models were not tested in another sample. Further studies may be required to validate the risk factors.

The ReMInDAR trial enrolled residents who were not frail and not cognitively impaired, thus caution must be exercised when generalising the results to a frailer aged-care population.

During the final months of the trial, which were affected by COVID-19 restrictions, some problems and adverse drug events may have been underreported. However, our analysis indicated that COVID-19 restrictions were not a risk factor for adverse drug events in this study.

5 Conclusion

We aimed to identify resident-level independent factors predicting risk of adverse drug events, with the ultimate goal to better recognise residents most at risk, to support interventions to provide better care. In residential aged-care facilities, medicines are often prescribed long-term. Pharmacists and aged-care staff play an important role in monitoring residents. Aged-care residents who demonstrate clearly identifiable characteristics, including poor cognition performance on MoCA, previous fall, and prescribed sedative or hypnotic agents, should be prioritised for pharmacists to perform medicine reviews. Upon identifying the PIMs, recommendations should be provided to discontinue the medicines. Furthermore, clinicians should identify and monitor changes in signs and symptoms that may indicate deterioration or adverse drug events in aged-care residents.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40266-022-00983-6>.

Acknowledgement This work was supported by the Australian Government Department of Health Pharmacy Trial Program. The Australian Government Department of Health reviewed the manuscript before submission but played no role in the study design, data collection, management, writing of manuscript or decision to submit the paper for publication.

Declarations

Authors' contributions As principal investigator, ER had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Conception and design: ER, GD, NPN, LB, NP, TLK. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: GD, ER, NPN, TLK. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: GD, NPN, ER, NP, TLK. Obtained funding: ER, DR, LKE, LB, NP, Parfitt, JW, RL. Administrative, technical, or material support: GD, ER, RLB, NP, TLK, AA, RL. Supervision: ER

Funding This work was supported by the Australian Government Department of Health Pharmacy Trial Program. The Australian Government Department of Health reviewed the manuscript before submission but played no role in the study design, data collection, management, writing of the manuscript or decision to submit the paper for publication.

Code and data availability De-identified data and codes can be requested from the corresponding author.

Conflicts of interests Gereltuya Dorj, Nibu Parameswaran Nair, Luke Bereznicki, Thu-Lan Kelly, Nicole Pratt, Lisa Kalisch Ellet, Andre Andrade, Debra Rowett, Joseph Whitehouse, Rebecca L. Bilton, Renly Lim, Imaina Widagdo and Elizabeth Roughead have no conflicts of interest to declare.

Ethical approval This study was approved by the Human Research Ethics Committee of the University of South Australia (ID: 0000036440) and the University of Tasmania (ID: H0017022).

Consent to participate Not applicable.

Consent for publication Not applicable.

Informed consent Not required for publication.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

References

1. Sluggett JK, Ilomäki J, Seaman KL, Corlis M, Bell JS. Medication management policy, practice and research in Australian residential aged care: current and future directions. *Pharmacol Res.* 2017;116:20–8.
2. Sluggett JK, Harrison SL, Ritchie LA, Clough AJ, Rigby D, Caughey GE, et al. High-risk medication use in older residents of long-term care facilities: prevalence, harms, and strategies to mitigate risks and enhance use. *Senior Care Pharmacist.* 2020;35(10):419–33.
3. Storms H, Marquet K, Aertgeerts B, Claes N. Prevalence of inappropriate medication use in residential long-term care facilities for the elderly: a systematic review. *Eur J Gen Pract.* 2017;23(1):69–77.
4. Palmer K, Villani ER, Vetrano DL, Cherubini A, Cruz-Jentoft AJ, Curtin D, et al. Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis. *Eur Geriatr Med.* 2019;10(1):9–36.
5. Handler SM, Wright RM, Ruby CM, Hanlon JT. Epidemiology of medication-related adverse events in nursing homes. *Am J Geriatr Pharmacother.* 2006;4(3):264–72.
6. Tenhunen ML, Smithers B, Tucker B. Identifying medication-related adverse drug events in nursing facilities in east Texas. *Consult Pharm.* 2016;31(8):436–9.
7. Tariq RA, Vashisht R, Sinha A, Scherbak Y. Medication dispensing errors and prevention. Treasure Island: StatPearls Publishing; 2018.
8. Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, et al. The incidence of adverse drug events in two large academic long-term care facilities. *Am J Med.* 2005;118(3):251–8.
9. Panel AGSBCUE, Fick DM, Semla TP, Steinman M, Beizer J, Brandt N, et al. American Geriatrics Society 2019 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. *J Am Geriatr Soc.* 2019;67(4):674–94.
10. Topinková E, Mádlová P, Fialová D, Klán J. New evidence-based criteria for evaluating the appropriateness of drug regimen in seniors. Criteria STOPP (screening tool of older person's prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). *Vnitr Lek.* 2008;54(12):1161–9.
11. Lipton HL, Bird JA. Drug utilization review in ambulatory settings: state of the science and directions for outcomes research. *Med Care.* 1993;31(12):1069–82.

12. Samsa GP, Hanlon JT, Schmader KE, Weinberger M, Clipp EC, Uttech KM, et al. A summated score for the medication appropriateness index: development and assessment of clinimetric properties including content validity. *J Clin Epidemiol*. 1994;47(8):891–6.
13. Pugh MJV, Hanlon JT, Zeber JE, Bierman A, Cornell J, Berlowitz DR. Assessing potentially inappropriate prescribing in the elderly Veterans Affairs population using the HEDIS 2006 quality measure. *J Manag Care Pharm*. 2006;12(7):537–45.
14. Xing XX, Zhu C, Liang HY, Wang K, Chu YQ, Zhao LB, et al. Associations between potentially inappropriate medications and adverse health outcomes in the elderly: a systematic review and meta-analysis. *Ann Pharmacother*. 2019;53(10):1005–19.
15. Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, et al. Withdrawal of antihypertensive drugs in older people. *Cochrane Database Syst Rev*. 2020;6(6):12572.
16. Kallin K, Jensen J, Olsson LL, Nyberg L, Gustafson Y. Why the elderly fall in residential care facilities, and suggested remedies. *J Fam Pract*. 2004;53(1):41–52.
17. Ailabouni N, Mangin D, Nishtala PS. DEFEAT-polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. *Int J Clin Pharm*. 2019;41(1):167–78.
18. Kosari S, McDerby N, Thomas J, Naunton M. Quality use of medicines in aged care facilities: a need for new models of care. *J Clin Pharm Ther*. 2018;43(4):591–3.
19. Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, et al. Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. *Arch Intern Med*. 1999;159(21):2553–60.
20. Field TS, Gurwitz JH, Avorn J, McCormick D, Jain S, Eckler M, et al. Risk factors for adverse drug events among nursing home residents. *Arch Intern Med*. 2001;161(13):1629–34.
21. Parameswaran Nair N, Chalmers L, Connolly M, Bereznicki BJ, Peterson GM, Curtain C, et al. Prediction of hospitalization due to adverse drug reactions in elderly community-dwelling patients (The PADR-EC Score). *PLoS ONE*. 2016;11(10):e0165757.
22. Saedder EA, Lisby M, Nielsen LP, Rungby J, Andersen LV, Bonnerup DK, et al. Detection of patients at high risk of medication errors: development and validation of an algorithm. *Basic Clin Pharmacol Toxicol*. 2016;118(2):143–9.
23. Petrovic M, Tangiisuran B, Rajkumar C, van der Cammen T, Onder G. Predicting the risk of adverse drug reactions in older inpatients: external validation of the gerontonet ADR risk score using the CRIME cohort. *Drugs Aging*. 2017;34(2):135–42.
24. Parekh N, Ali K, Davies JG, Stevenson JM, Banya W, Nyangoma S, et al. Medication-related harm in older adults following hospital discharge: development and validation of a prediction tool. *BMJ Qual Saf*. 2020;29(2):142–53.
25. Aged Care Financing Authority. Eighth report on the funding and financing of the aged care industry. Canberra, ACT: Aged Care Financing Authority; 2020.
26. Roughead EE, Lim R, Bereznicki L, Corlis M, Ellett LMK, Kang AC, et al. Effect of an ongoing pharmacist service to reduce medicine-induced deterioration and adverse reactions in aged-care facilities (nursing homes): a multicentre, randomised controlled trial (the ReMInDAR trial) (AA-21-1838.R2). *Age Ageing*. 2022;10(4):e32851.
27. Langa KM, Levine DA. The diagnosis and management of mild cognitive impairment: a clinical review. *JAMA*. 2014;312(23):2551–61.
28. Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. *JAMA Neurol*. 2016;73(6):721–32.
29. Ashfield TA, Syddall HE, Martin HJ, Dennison EM, Cooper C, Aihie SA. Grip strength and cardiovascular drug use in older people: findings from the Hertfordshire Cohort Study. *Age Ageing*. 2010;39(2):185–91.
30. Lee DSH, Markwardt S, Goeres L, Lee CG, Eckstrom E, Williams C, et al. Statins and physical activity in older men: the osteoporotic fractures in men study. *JAMA Intern Med*. 2014;174(8):1263–70.
31. Dent E, Kowal P, Hoogendijk EO. Frailty measurement in research and clinical practice: a review. *Eur J Intern Med*. 2016;31:3–10.
32. Brown RT, Diaz-Ramirez LG, Boscardin WJ, Lee SJ, Williams BA, Steinman MA. Association of functional impairment in middle age with hospitalization, nursing home admission, and death. *JAMA Intern Med*. 2019;179(5):668–75.
33. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther*. 1981;30(2):239–45.
34. Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. *Hosp Pharm*. 1992;27(6):538.
35. Jansen KM, Bell JS, Hilmer SN, Kirkpatrick CM, Ilomäki J, Le Couteur D, et al. Effects of changes in number of medications and drug burden index exposure on transitions between frailty states and death: the concord health and ageing in men project cohort study. *J Am Geriatr Soc*. 2016;64(1):89–95.
36. Cullinan S, O'Mahony D, O'Sullivan D, Byrne S. Use of a frailty index to identify potentially inappropriate prescribing and adverse drug reaction risks in older patients. *Age Ageing*. 2016;45(1):115–20.
37. Widagdo IS, Pratt N, Russell M, Roughead EE. Predictive performance of four frailty measures in an older Australian population. *Age Ageing*. 2015;44(6):967–72.
38. Lattanzio F, Landi F, Bustacchini S, Abbatecola AM, Corica F, Pranno L, et al. Geriatric conditions and the risk of adverse drug reactions in older adults. *Drug Saf*. 2012;35(1):55–61.
39. Eslinger D, Rowlands AV, Hurst TL, Catt M, Murray P, Eston RG. Validation of the GENEA Accelerometer. *Med Sci Sports Exerc*. 2011;43(6):1085–93.
40. Villafañe JH, Valdes K, Bertozzi L, Negrini S. Minimal clinically important difference of grip and pinch strength in women with thumb carpometacarpal osteoarthritis when compared to healthy subjects. *Rehabil Nurs*. 2017;42(3):139–45.
41. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing*. 2019;48(1):16–31.
42. Pourmotabbed A, Ghaedi E, Babaei A, Mohammadi H, Khazaei H, Jalili C, et al. Sleep duration and sarcopenia risk: a systematic review and dose-response meta-analysis. *Sleep Breath*. 2020;24(4):1267–78.
43. Fraysse F, Post D, Eston R, Kasai D, Rowlands AV, Parfitt G. Physical activity intensity cut-points for wrist-worn GENEAActive in older adults. *Front Sports Active Living*. 2021;2: 579278.
44. Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. *J Am Geriatr Soc*. 2005;53(4):695–9.
45. Australian Government Department of Health. Medicare Benefits Schedule (MBS). Department of Health, Australian Government; 2022.
46. Pahor M, Chrischilles EA, Guralnik JM, Brown SL, Wallace RB, Carbonin P. Drug data coding and analysis in epidemiologic studies. *Eur J Epidemiol*. 1994;10(4):405–11.
47. Van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. *J Stat Softw*. 2011;45:1–67.
48. Rubin DB. Multiple imputation for nonresponse in surveys. New York: John Wiley & Sons; 2004.

49. Rodwell L, Lee KJ, Romaniuk H, Carlin JB. Comparison of methods for imputing limited-range variables: a simulation study. *BMC Med Res Methodol.* 2014;14(1):1–11.
50. R Core Team. *R: A language and environment for statistical computing.* Vienna: R Foundation for Statistical Computing; 2013.
51. Hosmer D, Lemeshow S. *Applied logistic regression.* A Wiley-Interscience Publication. New York, Chichester. Weinheim: John Wiley & Sons, Inc.; 2000.
52. Gareth J, Daniela W, Trevor H, Robert T. *An introduction to statistical learning: with applications in R.* Springer; 2013.
53. Roughead L, Semple S. Literature review: medication safety in acute care in Australia. Australian Commission on Safety and Quality in Healthcare; 2008.
54. Bu Z, Huang A, Xue M, Li Q, Bai Y, Xu G. Cognitive frailty as a predictor of adverse outcomes among older adults: a systematic review and meta-analysis. *Brain Behav.* 2021;11(1): e01926.
55. Vatanabe IP, Pedroso RV, Teles RHG, Ribeiro JC, Manzine PR, Pott-Junior H, et al. A systematic review and meta-analysis on cognitive frailty in community-dwelling older adults: risk and associated factors. *Aging Ment Health.* 2022;26(3):464–76.
56. Zazzara MB, Palmer K, Vetrano DL, Carfi A, Graziano O. Adverse drug reactions in older adults: a narrative review of the literature. *Eur Geriatr Med.* 2021;12(3):463–73.
57. Waldron N, Hill A-M, Barker A. Falls prevention in older adults: assessment and management. *Aust Fam Physician.* 2012;41(12):930–5.
58. Deandrea S, Bravi F, Turati F, Lucenteforte E, La Vecchia C, Negri E. Risk factors for falls in older people in nursing homes and hospitals. A systematic review and meta-analysis. *Arch Gerontol Geriatr.* 2013;56(3):407–15.
59. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. *Arch Intern Med.* 2009;169(21):1952–60.
60. Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. *J Am Geriatr Soc.* 1999;47(1):30–9.
61. Jokanovic N, Tan EC, Dooley MJ, Kirkpatrick CM, Bell JS. Prevalence and factors associated with polypharmacy in long-term care facilities: a systematic review. *J Am Med Directors Assoc.* 2015;16(6):535.
62. Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Hanratty B. Adverse outcomes of polypharmacy in older people: systematic review of reviews. *J Am Med Dir Assoc.* 2020;21(2):181–7.